Paragon Care Limited (PGC) AI Stock Analysis

• Market Cap: €430.38M
• Dividend Yield: N/A
• Average Volume (3M): 501.29K
• Price to Earnings (P/E): 18.1
• Beta (1Y): 1.02
• Revenue Growth: 21.68%
• EPS Growth: 37.78%
• Country: AU
• Employees: 400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): <0.01
• Shares Outstanding: 1,655,305,400
• 10 Day Avg. Volume: 605,379
• 30 Day Avg. Volume: 501,285
• PEG Ratio: 0.78
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.17
• P/FCF Ratio: -26.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.50
• Price Target Upside: 126.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: AU$0.23 ▲(4.55% Upside)

Paragon Care Limited's overall stock score reflects significant financial challenges, including declining revenue and cash flow issues, coupled with bearish technical indicators. While the valuation is moderate, the lack of dividend yield and negative market momentum weigh heavily on the stock's attractiveness.

Positive Factors

Revenue Model

Paragon Care's diverse revenue streams from direct sales and service contracts provide a stable foundation, enhancing resilience against market fluctuations.

Partnerships

Strong partnerships with global manufacturers enable access to high-quality products, enhancing competitive advantage and market position.

Operational Efficiency

Improved EBIT and EBITDA margins indicate better operational efficiency, which can lead to enhanced profitability over time.

Negative Factors

Revenue Decline

A sharp decline in revenue growth reflects challenges in market demand or competitive pressures, potentially impacting long-term financial health.

Cash Flow Challenges

Negative cash flow indicates difficulties in sustaining operations and investments, posing risks to financial stability and growth.

Low Profitability Margins

Low profitability margins suggest limited ability to convert sales into profit, challenging long-term sustainability and shareholder returns.

Paragon Care Limited Business Overview & Revenue Model

Company Description

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.

How the Company Makes Money

Paragon Care generates revenue primarily through the sale of medical equipment and consumables to hospitals, healthcare facilities, and aging care services. The company's revenue model is based on direct sales, distribution agreements, and service contracts. Key revenue streams include the sale of surgical instruments, diagnostic devices, and rehabilitation products. Additionally, PGC benefits from significant partnerships with leading global manufacturers, allowing them to offer a wide range of high-quality products. The company also engages in value-added services, such as equipment maintenance and training, contributing further to its earnings.

Paragon Care Limited Financial Statement Overview

Summary

Paragon Care Limited is facing financial challenges with declining revenue and low profitability margins. Despite some operational efficiency gains, the company struggles with cash flow management and moderate leverage.

Income Statement

Paragon Care Limited has experienced a significant decline in revenue growth, with a negative growth rate of -22.46% in the most recent year. The gross profit margin is relatively low at 8.97%, indicating limited profitability from core operations. The net profit margin is also low at 0.57%, reflecting challenges in converting revenue into profit. However, there is a slight improvement in EBIT and EBITDA margins compared to previous years, suggesting some operational efficiency gains.

Balance Sheet

The company maintains a moderate debt-to-equity ratio of 0.93, indicating a balanced approach to leveraging. Return on equity is modest at 6.45%, showing some ability to generate returns for shareholders. The equity ratio stands at 25.84%, suggesting a reasonable proportion of assets financed by equity. Overall, the balance sheet reflects moderate financial stability with manageable leverage.

Cash Flow

Paragon Care Limited faces challenges in cash flow management, with negative operating cash flow and free cash flow in the latest period. The free cash flow growth rate is high at 687.12%, but this is from a negative base, indicating volatility. The operating cash flow to net income ratio is negative, highlighting difficulties in converting accounting profits into cash. The free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.61B	3.61B	2.97B	307.63M	237.62M	235.84M
Gross Profit	324.00M	324.00M	176.07M	51.68M	36.58M	33.41M
EBITDA	89.81M	89.81M	43.18M	37.07M	23.96M	26.54M
Net Income	20.57M	20.57M	8.38M	12.80M	6.63M	8.28M
Balance Sheet
Total Assets	1.23B	1.23B	1.13B	448.52M	438.44M	291.92M
Cash, Cash Equivalents and Short-Term Investments	21.90M	21.90M	19.94M	970.00K	46.20M	33.20M
Total Debt	296.52M	296.52M	251.83M	122.14M	131.26M	113.01M
Total Liabilities	915.04M	915.04M	838.97M	196.56M	196.31M	170.40M
Stockholders Equity	319.00M	319.00M	291.92M	18.88M	235.82M	121.52M
Cash Flow
Free Cash Flow	-23.04M	-23.04M	25.14M	-3.30M	14.42M	22.18M
Operating Cash Flow	-11.35M	-11.35M	44.45M	17.75M	19.03M	27.46M
Investing Cash Flow	-16.64M	-16.64M	-19.52M	-31.75M	7.07M	-18.80M
Financing Cash Flow	28.65M	28.65M	-5.95M	-10.00M	-11.93M	32.00K

Paragon Care Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.29, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 31.72 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PGC.

Paragon Care Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACL	71 Outperform	AU$541.16M	16.33	18.59%	4.45%	6.73%	37.16%
SIG	53 Neutral	€33.76B	58.10	―	0.45%	―	―
BOT	53 Neutral	AU$226.63M	-2.56	-90.93%	―	456.50%	-457.14%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HLS	50 Neutral	AU$700.72M	-1.31	-67.21%	―	-23.02%	33.11%
PGC	46 Neutral	€430.38M	18.15	6.74%	―	21.68%	37.78%
MYX	38 Underperform	AU$246.99M	-2.62	-21.13%	―	5.07%	46.14%

Paragon Care Limited Corporate Events

Paragon Care Expands Asian Footprint with Haju Medical Acquisition

Paragon Care Limited has announced its acquisition of Haju Medical, a leading provider of medical aesthetic services and technology in Indonesia. This strategic acquisition is expected to enhance Paragon Care’s presence in the Asia Pacific region and complement its existing business operations in Thailand and other emerging markets. The acquisition, valued at A$70 million, is anticipated to be earnings accretive for Paragon Care in FY26 and will be funded through existing working capital facilities. The completion of the acquisition is expected by January 2026, subject to customary conditions.

Paragon Care Limited Successfully Concludes 2025 AGM with Strong Shareholder Support

Paragon Care Limited held its 2025 Annual General Meeting, where all resolutions, including the adoption of the remuneration report, election and re-election of directors, adoption of an omnibus equity plan, and issuance of performance rights to the CEO, were carried with overwhelming support. This indicates strong shareholder confidence in the company’s leadership and strategic direction, potentially strengthening its position in the healthcare industry.

Paragon Care Limited Reports Successful Integration and Future Growth Prospects at 2025 AGM

Paragon Care Limited’s 2025 Annual General Meeting highlighted the successful integration of CH2, Oborne Health Supplies, and ParagonCare, with ongoing improvements in IT and finance systems. The company launched new business units in aesthetics, robotics, and dental, and completed the acquisition of Somnotec Group to expand its Asian operations. Despite higher debt levels due to non-payment by Infinity Retail Pharmacy Group and high stock levels, the company is working on debt reduction plans. The transition of CEO duties from David Collins to Carmen Riley is progressing smoothly, and the company is focused on future growth opportunities, with potential dividend considerations for shareholders.

Paragon Care Expands APAC Presence with Somnotec Acquisition

Paragon Care Limited has announced the acquisition of Somnotec Group, a distributor of medical devices in Southeast Asia, to expand its footprint in the region. This strategic acquisition is expected to enhance Paragon Care’s service capabilities across the Asia Pacific, with the deal valued at SGD24 million. The acquisition is anticipated to be earnings accretive by FY26 and is subject to regulatory approvals and other conditions.

Paragon Care Director Increases Shareholding

Paragon Care Limited has announced a change in the director’s interest, with Director David Collins acquiring an additional 640,167 ordinary shares through an on-market trade. This acquisition increases his indirect holding to 472,507,317 shares, reflecting a strategic move that may influence the company’s market perception and stakeholder confidence.

Paragon Care Director Increases Shareholding

Paragon Care Limited announced a change in the director’s interest, with Director David Collins acquiring an additional 105,114 ordinary shares through an on-market trade. This acquisition increases his indirect holding to 471,867,150 shares, potentially indicating confidence in the company’s future performance and stability, which may positively influence stakeholder perceptions.

Paragon Care Limited Announces CFO Resignation

Paragon Care Limited announced the resignation of its Chief Financial Officer, Marcus Crowe, who is leaving to pursue other opportunities. The company will begin a formal search for a new CFO and will update stakeholders as necessary. The board expressed gratitude for Crowe’s contributions, with CEO Carmen Riley wishing him success in his future endeavors.

Paragon Care Director Increases Shareholding, Signaling Confidence

Paragon Care Limited announced a change in the director’s interest, with Peter Egglestone acquiring an additional 200,000 ordinary shares through an on-market trade, increasing his indirect holding to 300,000 shares. This move could indicate confidence in the company’s future prospects and may have implications for stakeholders regarding the company’s market positioning and potential growth.

Paragon Care Limited Reinforces Commitment to Corporate Governance in 2025 Statement

Paragon Care Limited’s 2025 Corporate Governance Statement outlines the company’s adherence to the ASX Corporate Governance Council Principles and Recommendations. The statement emphasizes the Board’s commitment to strong governance practices, strategic oversight, and stakeholder value enhancement. It details the roles and responsibilities of the Board, the appointment process for directors, and the company’s diversity and inclusion initiatives. The statement reflects Paragon Care’s dedication to maintaining investor confidence and ensuring the company’s long-term success.

Paragon Care Limited Releases 2025 Corporate Governance Statement

Paragon Care Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This announcement reinforces Paragon Care’s dedication to maintaining high governance standards, potentially strengthening stakeholder trust and enhancing its industry reputation.

Paragon Care Limited Releases FY25 Audited Financial Results

Paragon Care Limited has released its audited financial results for the fiscal year ending June 30, 2025. The company reported no change in profit after tax attributable to shareholders from its preliminary report. Key financial adjustments include a retrospective restatement of intangible asset valuations and a reclassification of a $125 million debt from non-current to current. Despite a significant outstanding debt from a retail pharmacy group, Paragon Care is actively working on recovery and does not foresee any impact on its financial arrangements. The company is focused on growth through both organic expansion and acquisitions, particularly in Asia.

Paragon Care Limited: 2025 Annual Report Highlights Growth and Commitment to ESG

Paragon Care Limited’s Annual Report for 2025 highlights its position as a diversified healthcare leader in the Asia Pacific, emphasizing its commitment to simplifying and enhancing healthcare accessibility. The report underscores the company’s strategic growth following its merger with Clifford Hallam and its dedication to environmental, social, and governance (ESG) principles, which are crucial for its stakeholders and industry positioning.